請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/33014完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 王萬波 | |
| dc.contributor.author | Zong-Keng Kuo | en |
| dc.contributor.author | 郭宗鏗 | zh_TW |
| dc.date.accessioned | 2021-06-13T04:21:57Z | - |
| dc.date.available | 2011-08-03 | |
| dc.date.copyright | 2006-08-03 | |
| dc.date.issued | 2006 | |
| dc.date.submitted | 2006-07-23 | |
| dc.identifier.citation | Adams, J.M. and Cory, S. (2001) Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci, 26, 61-66.
Allred, D.C., Clark, G.M., Tandon, A.K., Molina, R., Tormey, D.C., Osborne, C.K., Gilchrist, K.W., Mansour, E.G., Abeloff, M., Eudey, L. and et al. (1992) HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol, 10, 599-605. Andersson, M.G., Haasnoot, P.C., Xu, N., Berenjian, S., Berkhout, B. and Akusjarvi, G. (2005) Suppression of RNA interference by adenovirus virus-associated RNA. J Virol, 79, 9556-9565. Arteaga, C.L. (2003) ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res, 284, 122-130. Barnett, B.G., Crews, C.J. and Douglas, J.T. (2002) Targeted adenoviral vectors. Biochim Biophys Acta, 1575, 1-14. Baselga, J., Norton, L., Albanell, J., Kim, Y.M. and Mendelsohn, J. (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res, 58, 2825-2831. Bassik, M.C., Scorrano, L., Oakes, S.A., Pozzan, T. and Korsmeyer, S.J. (2004) Phosphorylation of BCL-2 regulates ER Ca2+ homeostasis and apoptosis. Embo J, 23, 1207-1216. Bitko, V., Musiyenko, A., Shulyayeva, O. and Barik, S. (2005) Inhibition of respiratory viruses by nasally administered siRNA. Nat Med, 11, 50-55. Brodowicz, T., Wiltschke, C., Budinsky, A.C., Krainer, M., Steger, G.G. and Zielinski, C.C. (1997) Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Int J Cancer, 73, 875-879. Chang, C.Y., Lin, Y.M., Lee, W.P., Hsu, H.H. and Chen, E.I. (2006) Involvement of Bcl-X(L) deamidation in E1A-mediated cisplatin sensitization of ovarian cancer cells. Oncogene, 25, 2656-2665. Chen, H. and Hung, M.C. (1997) Involvement of co-activator p300 in the transcriptional regulation of the HER-2/neu gene. J Biol Chem, 272, 6101-6104. Chen, J.S., Lan, K. and Hung, M.C. (2003) Strategies to target HER2/neu overexpression for cancer therapy. Drug Resist Updat, 6, 129-136. Cho, H.S., Mason, K., Ramyar, K.X., Stanley, A.M., Gabelli, S.B., Denney, D.W., Jr. and Leahy, D.J. (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature, 421, 756-760. Choudhury, A., Charo, J., Parapuram, S.K., Hunt, R.C., Hunt, D.M., Seliger, B. and Kiessling, R. (2004) Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer, 108, 71-77. Coussens, L., Yang-Feng, T.L., Liao, Y.C., Chen, E., Gray, A., McGrath, J., Seeburg, P.H., Libermann, T.A., Schlessinger, J., Francke, U. and et al. (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 230, 1132-1139. Danielsen, A.J. and Maihle, N.J. (2002) The EGF/ErbB receptor family and apoptosis. Growth Factors, 20, 1-15. Dankort, D.L. and Muller, W.J. (2000) Signal transduction in mammary tumorigenesis: a transgenic perspective. Oncogene, 19, 1038-1044. Deverman, B.E., Cook, B.L., Manson, S.R., Niederhoff, R.A., Langer, E.M., Rosova, I., Kulans, L.A., Fu, X., Weinberg, J.S., Heinecke, J.W., Roth, K.A. and Weintraub, S.J. (2002) Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage. Cell, 111, 51-62. Dorsett, Y. and Tuschl, T. (2004) siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov, 3, 318-329. Drebin, J.A., Stern, D.F., Link, V.C., Weinberg, R.A. and Greene, M.I. (1984) Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature, 312, 545-548. Dykxhoorn, D.M. and Lieberman, J. (2005) The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu Rev Med, 56, 401-423. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K. and Tuschl, T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 494-498. Faltus, T., Yuan, J., Zimmer, B., Kramer, A., Loibl, S., Kaufmann, M. and Strebhardt, K. (2004) Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia, 6, 786-795. Felip, E., Del Campo, J.M., Rubio, D., Vidal, M.T., Colomer, R. and Bermejo, B. (1995) Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer, 75, 2147-2152. Ge, Q., Filip, L., Bai, A., Nguyen, T., Eisen, H.N. and Chen, J. (2004) Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A, 101, 8676-8681. Gilmore, I.R., Fox, S.P., Hollins, A.J., Sohail, M. and Akhtar, S. (2004) The design and exogenous delivery of siRNA for post-transcriptional gene silencing. J Drug Target, 12, 315-340. Giri, D.K., Ali-Seyed, M., Li, L.Y., Lee, D.F., Ling, P., Bartholomeusz, G., Wang, S.C. and Hung, M.C. (2005) Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol Cell Biol, 25, 11005-11018. Gonzalez, V.M., Fuertes, M.A., Alonso, C. and Perez, J.M. (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol, 59, 657-663. Grinspan, J.B., Marchionni, M.A., Reeves, M., Coulaloglou, M. and Scherer, S.S. (1996) Axonal interactions regulate Schwann cell apoptosis in developing peripheral nerve: neuregulin receptors and the role of neuregulins. J Neurosci, 16, 6107-6118. Gross, M.E., Shazer, R.L. and Agus, D.B. (2004) Targeting the HER-kinase axis in cancer. Semin Oncol, 31, 9-20. Gusterson, B.A., Gelber, R.D., Goldhirsch, A., Price, K.N., Save-Soderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C.M., Golouh, R., Reed, R. and et al. (1992) Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol, 10, 1049-1056. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M.P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C.S., Pawliuk, R., Morillon, E., Sorensen, R., Forster, A., Fraser, P., Cohen, J.I., de Saint Basile, G., Alexander, I., Wintergerst, U., Frebourg, T., Aurias, A., Stoppa-Lyonnet, D., Romana, S., Radford-Weiss, I., Gross, F., Valensi, F., Delabesse, E., Macintyre, E., Sigaux, F., Soulier, J., Leiva, L.E., Wissler, M., Prinz, C., Rabbitts, T.H., Le Deist, F., Fischer, A. and Cavazzana-Calvo, M. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302, 415-419. Harari, D. and Yarden, Y. (2000) Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene, 19, 6102-6114. He, T.C., Zhou, S., da Costa, L.T., Yu, J., Kinzler, K.W. and Vogelstein, B. (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A, 95, 2509-2514. Holbro, T., Civenni, G. and Hynes, N.E. (2003) The ErbB receptors and their role in cancer progression. Exp Cell Res, 284, 99-110. Hong, R.L., Spohn, W.H. and Hung, M.C. (1999) Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin Cancer Res, 5, 1884-1891. Hortobagyi, G.N., Ueno, N.T., Xia, W., Zhang, S., Wolf, J.K., Putnam, J.B., Weiden, P.L., Willey, J.S., Carey, M., Branham, D.L., Payne, J.Y., Tucker, S.D., Bartholomeusz, C., Kilbourn, R.G., De Jager, R.L., Sneige, N., Katz, R.L., Anklesaria, P., Ibrahim, N.K., Murray, J.L., Theriault, R.L., Valero, V., Gershenson, D.M., Bevers, M.W., Huang, L., Lopez-Berestein, G. and Hung, M.C. (2001) Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol, 19, 3422-3433. Hynes, N.E. and Lane, H.A. (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer, 5, 341-354. Hynes, N.E. and Stern, D.F. (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta, 1198, 165-184. Igney, F.H. and Krammer, P.H. (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer, 2, 277-288. Jones, F.E. and Stern, D.F. (1999) Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation. Oncogene, 18, 3481-3490. Kanegae, Y., Makimura, M. and Saito, I. (1994) A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol, 47, 157-166. Kartalou, M. and Essigmann, J.M. (2001) Mechanisms of resistance to cisplatin. Mutat Res, 478, 23-43. Kawasaki, H. and Taira, K. (2004) Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature, 431, 211-217. Kim, R., Tanabe, K., Uchida, Y., Osaki, A. and Toge, T. (2002) The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review). Oncol Rep, 9, 3-9. King, C.R., Kraus, M.H. and Aaronson, S.A. (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science, 229, 974-976. Klapper, L.N., Waterman, H., Sela, M. and Yarden, Y. (2000) Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res, 60, 3384-3388. Klos, K.S., Wyszomierski, S.L., Sun, M., Tan, M., Zhou, X., Li, P., Yang, W., Yin, G., Hittelman, W.N. and Yu, D. (2006) ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res, 66, 2028-2037. Kumar, R. and Yarmand-Bagheri, R. (2001) The role of HER2 in angiogenesis. Semin Oncol, 28, 27-32. Kunisue, H., Kurebayashi, J., Otsuki, T., Tang, C.K., Kurosumi, M., Yamamoto, S., Tanaka, K., Doihara, H., Shimizu, N. and Sonoo, H. (2000) Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. Br J Cancer, 82, 46-51. Lakka, S.S., Gondi, C.S., Dinh, D.H., Olivero, W.C., Gujrati, M., Rao, V.H., Sioka, C. and Rao, J.S. (2005) Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. J Biol Chem, 280, 21882-21892. Lee, K.F., Simon, H., Chen, H., Bates, B., Hung, M.C. and Hauser, C. (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature, 378, 394-398. Levkowitz, G., Oved, S., Klapper, L.N., Harari, D., Lavi, S., Sela, M. and Yarden, Y. (2000) c-Cbl is a suppressor of the neu oncogene. J Biol Chem, 275, 35532-35539. Lin, Y.C., Peng, J.M. and Wang, W.B. (2000) The N-terminal common domain of simian virus 40 large T and small t antigens acts as a transformation suppressor of the HER-2/neu oncogene. Oncogene, 19, 2704-2713. Lu, S. and Cullen, B.R. (2004) Adenovirus VA1 noncoding RNA can inhibit small interfering RNA and MicroRNA biogenesis. J Virol, 78, 12868-12876. Madhusudan, S., Tamir, A., Bates, N., Flanagan, E., Gore, M.E., Barton, D.P., Harper, P., Seckl, M., Thomas, H., Lemoine, N.R., Charnock, M., Habib, N.A., Lechler, R., Nicholls, J., Pignatelli, M. and Ganesan, T.S. (2004) A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res, 10, 2986-2996. Marmor, M.D., Skaria, K.B. and Yarden, Y. (2004) Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys, 58, 903-913. Matin, A. and Hung, M.C. (1993) Negative regulation of the neu promoter by the SV40 large T antigen. Cell Growth Differ, 4, 1051-1056. Mendelsohn, J. and Baselga, J. (2000) The EGF receptor family as targets for cancer therapy. Oncogene, 19, 6550-6565. Molina, M.A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J. and Baselga, J. (2001) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res, 61, 4744-4749. Newman, S.P., Bates, N.P., Vernimmen, D., Parker, M.G. and Hurst, H.C. (2000) Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene, 19, 490-497. Nieto, Y., Vredenburgh, J.J., Shpall, E.J., Bearman, S.I., McSweeney, P.A., Chao, N., Rizzieri, D., Gasparetto, C., Matthes, S., Baron, A.E. and Jones, R.B. (2004) Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. Clin Cancer Res, 10, 7136-7143. Ozcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., Hubner, N., Chien, K.R., Birchmeier, C. and Garratt, A.N. (2002) Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A, 99, 8880-8885. Padhy, L.C., Shih, C., Cowing, D., Finkelstein, R. and Weinberg, R.A. (1982) Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell, 28, 865-871. Park, S.K., Miller, R., Krane, I. and Vartanian, T. (2001) The erbB2 gene is required for the development of terminally differentiated spinal cord oligodendrocytes. J Cell Biol, 154, 1245-1258. Peeper, D.S. and Zantema, A. (1993) Adenovirus-E1A proteins transform cells by sequestering regulatory proteins. Mol Biol Rep, 17, 197-207. Pegram, M.D., Finn, R.S., Arzoo, K., Beryt, M., Pietras, R.J. and Slamon, D.J. (1997) The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene, 15, 537-547. Pegram, M.D., Lopez, A., Konecny, G. and Slamon, D.J. (2000) Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol, 27, 21-25; discussion 92-100. Perissi, V., Menini, N., Cottone, E., Capello, D., Sacco, M., Montaldo, F. and De Bortoli, M. (2000) AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen. Oncogene, 19, 280-288. Poruchynsky, M.S., Wang, E.E., Rudin, C.M., Blagosklonny, M.V. and Fojo, T. (1998) Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res, 58, 3331-3338. Rait, A.S., Pirollo, K.F., Rait, V., Krygier, J.E., Xiang, L. and Chang, E.H. (2001) Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer. Cancer Gene Ther, 8, 728-739. Ravagnan, L., Roumier, T. and Kroemer, G. (2002) Mitochondria, the killer organelles and their weapons. J Cell Physiol, 192, 131-137. Roh, H., Pippin, J., Boswell, C. and Drebin, J.A. (1998) Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu. J Surg Res, 77, 85-90. Roh, H., Pippin, J.A., Green, D.W., Boswell, C.B., Hirose, C.T., Mokadam, N. and Drebin, J.A. (2000) HER2/neu antisense targeting of human breast carcinoma. Oncogene, 19, 6138-6143. Roskoski, R., Jr. (2004) The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun, 319, 1-11. Russell, W.C. (2000) Update on adenovirus and its vectors. J Gen Virol, 81, 2573-2604. Ruvolo, P.P., Deng, X. and May, W.S. (2001) Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia, 15, 515-522. Ryther, R.C., Flynt, A.S., Phillips, J.A., 3rd and Patton, J.G. (2005) siRNA therapeutics: big potential from small RNAs. Gene Ther, 12, 5-11. Samakoglu, S., Lisowski, L., Budak-Alpdogan, T., Usachenko, Y., Acuto, S., Di Marzo, R., Maggio, A., Zhu, P., Tisdale, J.F., Riviere, I. and Sadelain, M. (2006) A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nat Biotechnol, 24, 89-94. Scherer, L.J. and Rossi, J.J. (2003) Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol, 21, 1457-1465. Schiff, R., Massarweh, S., Shou, J. and Osborne, C.K. (2003) Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res, 9, 447S-454S. Schwarz, D.S., Hutvagner, G., Du, T., Xu, Z., Aronin, N. and Zamore, P.D. (2003) Asymmetry in the assembly of the RNAi enzyme complex. Cell, 115, 199-208. Semba, K., Kamata, N., Toyoshima, K. and Yamamoto, T. (1985) A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci U S A, 82, 6497-6501. Shih, C., Padhy, L.C., Murray, M. and Weinberg, R.A. (1981) Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature, 290, 261-264. Siddik, Z.H. (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 22, 7265-7279. Sliwkowski, M.X., Lofgren, J.A., Lewis, G.D., Hotaling, T.E., Fendly, B.M. and Fox, J.A. (1999) Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol, 26, 60-70. Song, E., Lee, S.K., Dykxhoorn, D.M., Novina, C., Zhang, D., Crawford, K., Cerny, J., Sharp, P.A., Lieberman, J., Manjunath, N. and Shankar, P. (2003) Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol, 77, 7174-7181. Song, E., Zhu, P., Lee, S.K., Chowdhury, D., Kussman, S., Dykxhoorn, D.M., Feng, Y., Palliser, D., Weiner, D.B., Shankar, P., Marasco, W.A. and Lieberman, J. (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol, 23, 709-717. Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., John, M., Kesavan, V., Lavine, G., Pandey, R.K., Racie, T., Rajeev, K.G., Rohl, I., Toudjarska, I., Wang, G., Wuschko, S., Bumcrot, D., Koteliansky, V., Limmer, S., Manoharan, M. and Vornlocher, H.P. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 432, 173-178. Sumimoto, H., Yamagata, S., Shimizu, A., Miyoshi, H., Mizuguchi, H., Hayakawa, T., Miyagishi, M., Taira, K. and Kawakami, Y. (2005) Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene Ther, 12, 95-100. Suzuki, T., Anderegg, B., Ohkawa, T., Irie, A., Engebraaten, O., Halks-Miller, M., Holm, P.S., Curiel, D.T., Kashani-Sabet, M. and Scanlon, K.J. (2000) Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells. Gene Ther, 7, 241-248. Tegerstedt, K., Lindencrona, J.A., Curcio, C., Andreasson, K., Tullus, C., Forni, G., Dalianis, T., Kiessling, R. and Ramqvist, T. (2005) A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res, 65, 5953-5957. Thornberry, N.A. and Lazebnik, Y. (1998) Caspases: enemies within. Science, 281, 1312-1316. Tsai, C.M., Chang, K.T., Li, L., Perng, R.P. and Yang, L.Y. (2000) Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells. Jpn J Cancer Res, 91, 213-222. Tsai, C.M., Chang, K.T., Perng, R.P., Mitsudomi, T., Chen, M.H., Kadoyama, C. and Gazdar, A.F. (1993) Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst, 85, 897-901. Tsai, C.M., Yu, D., Chang, K.T., Wu, L.H., Perng, R.P., Ibrahim, N.K. and Hung, M.C. (1995) Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. J Natl Cancer Inst, 87, 682-684. Uchida, H., Tanaka, T., Sasaki, K., Kato, K., Dehari, H., Ito, Y., Kobune, M., Miyagishi, M., Taira, K., Tahara, H. and Hamada, H. (2004) Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther, 10, 162-171. Ueno, N.T., Bartholomeusz, C., Herrmann, J.L., Estrov, Z., Shao, R., Andreeff, M., Price, J., Paul, R.W., Anklesaria, P., Yu, D. and Hung, M.C. (2000) E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res, 6, 250-259. Ueno, N.T., Yu, D. and Hung, M.C. (1997) Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene, 15, 953-960. Urban-Klein, B., Werth, S., Abuharbeid, S., Czubayko, F. and Aigner, A. (2005) RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther, 12, 461-466. van der Geer, P., Hunter, T. and Lindberg, R.A. (1994) Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol, 10, 251-337. Vivanco, I. and Sawyers, C.L. (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer, 2, 489-501. Wang, H.G., Pathan, N., Ethell, I.M., Krajewski, S., Yamaguchi, Y., Shibasaki, F., McKeon, F., Bobo, T., Franke, T.F. and Reed, J.C. (1999) Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science, 284, 339-343. Wang, S.C., Lien, H.C., Xia, W., Chen, I.F., Lo, H.W., Wang, Z., Ali-Seyed, M., Lee, D.F., Bartholomeusz, G., Ou-Yang, F., Giri, D.K. and Hung, M.C. (2004) Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell, 6, 251-261. Weinstein, I.B. (2002) Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science, 297, 63-64. Wen, C.C., Cheng, S.A., Hsuen, S.P., Huang, Y.L., Kuo, Z.K., Lee, H.F., Kuo, C.H., Du, J.L. and Wang, W.B. (2006) SV40 T/t-common polypeptide specifically induces apoptosis in human cancer cells that overexpress HER2/neu. Cancer Res, 66, 5847-5857. Xing, X., Matin, A., Yu, D., Xia, W., Sorgi, F., Huang, L. and Hung, M.C. (1996) Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer. Cancer Gene Ther, 3, 168-174. Yang, G., Cai, K.Q., Thompson-Lanza, J.A., Bast, R.C., Jr. and Liu, J. (2004) Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem, 279, 4339-4345. Yoo, G.H., Hung, M.C., Lopez-Berestein, G., LaFollette, S., Ensley, J.F., Carey, M., Batson, E., Reynolds, T.C. and Murray, J.L. (2001) Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res, 7, 1237-1245. Yu, D. and Hung, M.C. (2000) Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene, 19, 6115-6121. Yu, D., Liu, B., Tan, M., Li, J., Wang, S.S. and Hung, M.C. (1996) Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene, 13, 1359-1365. Yu, D., Matin, A., Xia, W., Sorgi, F., Huang, L. and Hung, M.C. (1995) Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene, 11, 1383-1388. Yu, D., Shi, D., Scanlon, M. and Hung, M.C. (1993) Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A. Cancer Res, 53, 5784-5790. Yu, D., Suen, T.C., Yan, D.H., Chang, L.S. and Hung, M.C. (1990) Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci U S A, 87, 4499-4503. Yu, D.H., Scorsone, K. and Hung, M.C. (1991) Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene. Mol Cell Biol, 11, 1745-1750. Zhang, L., Chang, C.J., Bacus, S.S. and Hung, M.C. (1995) Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. Cancer Res, 55, 3890-3896. Zhang, L., Lau, Y.K., Xia, W., Hortobagyi, G.N. and Hung, M.C. (1999) Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res, 5, 343-353. Zhang, Y., Yu, D., Xia, W. and Hung, M.C. (1995) HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene, 10, 1947-1954. Zhang, Y., Zhang, Y.F., Bryant, J., Charles, A., Boado, R.J. and Pardridge, W.M. (2004) Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res, 10, 3667-3677. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/33014 | - |
| dc.description.abstract | HER2/neu proto-oncogene是epidermal growth factor receptor(EGFR)家族成員之一。在許多癌症如卵巢癌、乳癌、肺癌、腎癌、結腸癌、胃癌等等，常有HER2/neu大量表現的現象。HER2/neu大量表現的癌症常伴隨著較強的轉移能力、血管新生能力、抗藥性及較差治癒率等特性，因此HER2/neu成為癌症治療上一個重要的標的。目前已有許多抑制HER2/neu表現及活性的方法，經由抑制HER2/neu，這些方法皆能有效抑制HER2/neu-overexpressing癌症。siRNA是抑制基因表現的有力工具，我們實驗室已篩選到可以抑制HER2/neu的siRNA。為了提高攜帶siRNA進入細胞的效率，本實驗室利用重組腺病毒作為攜帶針對HER2/neu的 siRNA的載體(rAdv-siHER2)，並想探討rAdv-siHER2是否可作為HER2/neu-overexpressing癌症的基因療法。結果發現rAdv-siHER2可以抑制HER2/neu-overexpressing癌細胞株BT-474、MDA-MB-453、SK-OV-3-sub1及SK-OK-3-ip1中HER2/neu的表現量。rAdv-siHER2感染HER2/neu-overexpressing癌細胞株後，發現細胞週期中sub-G1比例增加及PARP出現被切割的小片段，但是在HER2/neu low-expressing癌細胞株MDA-MB-231、MCF-7、HeLa及NPC-TW04及正常細胞株ECV304並沒有這些現象。代表rAdv-siHER2可專一性地促進HER2/neu-overexpressing癌細胞走向凋亡。此外，rAdv-siHER2能有效抑制HER2/neu-overexpressing癌細胞在柔軟瓊脂中形成的聚落數，而對HER2/neu low-expressing癌細胞影響不大。rAdv-siHER2感染BT-474後，也能減少HER2/neu下游訊息傳遞分子ERK1/2及Akt被活化的現象。此外，將rAdv-siHER2注射入腫瘤中，可以抑制SK-OV-3-ip1腫瘤在NOD/SCID小鼠皮下的生長。最後，rAdv-siHER2加上抗癌藥物CDDP (cisplatin)複合處理後，更能促進 CDDP誘發HER2/neu-overexpressing癌細胞凋亡的能力。綜合以上結果， rAdv-siHER2未來有潛力開發作為治療HER2/neu-overexpressing癌細胞的基因療法之一。 | zh_TW |
| dc.description.abstract | HER2/neu proto-oncogene is a member of epidermal growth factor receptor family. Overexpression and amplification of HER2/neu is found in many types of human cancers, including ovary, breast, lung, kindey, colon and gastrointestinal cancers. Overexpression of HER2/neu in cancers is correlated with enhanced metastasis, angiogenesis, and chemo-resistance, and poor prognosis, therefore treatment of HER2/neu-overexpressing cancers has become an urgent issue in cancer therapy. Inhibition of HER2/neu expression has been shown to be able to suppress HER2/neu-overexpressing cancers. Many strategies have been developed to inhibit HER2/neu in hope to cure this devastating disease. In this study, we chose to use siRNA against HER2/neu to suppress HER2/neu-overexpressing cancer cells. We have constructed a recombinant adenovirus expressing HER2/neu siRNA (named rAdv-siHER2). We demonstrated that rAdv-siHER2 could effectively inhibit HER2/neu expression in various HER2/neu-overexpressing cancer cell lines. This inhibition of HER2/neu expression by rAdv-siHER2 can lead to inhibition of ERK and AKT activities, both of which are downstream signaling molecules of HER2/neu and are required for cell proliferation and survival.
In accordance with its ability to inhibit HER2/neu expression, rAdv-siHER2 was shown, by sub-G1 analysis and PARP cleavage assay, to be able to specifically induce apoptosis in HER2/neu-overexpressing cancer cell lines (BT-474, MDA-MB-453, SK-OV-3-sub1 and SK-OV-3-ip1), but not in HER2/neu low-expressing cancer cell lines (MDA-MB-231, MCF-7, HeLa and NPC-TW04) and non-transformed cell line (ECV304). We also found that rAdv-siHER2 could specifically inhibit the soft-agar colony-forming ability of the HER2/neu-overexpressing cancer cell lines, but not that of the HER2/neu low-expressing cancer cell lines. Moreover, intratumoral injection of rAdv-siHER2 could effciently suppress the growth of established subcutaneous SK-OV-3-ip1 tumor on NOD/SCID mice. Finally, we demonstrated that rAdv-siHER2 could sensitize HER2/neu-overexpressing cancer cell lines, but not HER2/neu low-expressing cancer cell lines, to chemotherapeutic agent, cisplatin (CDDP). Taken together, these data suggest that rAdv-siHER2 has the potential to be developed into a gene therapy agent specifically against HER2/neu-overexpressing cancers. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T04:21:57Z (GMT). No. of bitstreams: 1 ntu-95-R93445106-1.pdf: 883597 bytes, checksum: 2b2ddba7bcfe0ccd2998f9feb9edd51d (MD5) Previous issue date: 2006 | en |
| dc.description.tableofcontents | 中文摘要……………………………………………………………… 1
英文摘要……………………………………………………………… 3 序言…………………………………………………………………… 5 研究目標………………………………………………………………17 材料與方法……………………………………………………………18 結果……………………………………………………………………30 討論……………………………………………………………………38 附圖……………………………………………………………………47 參考資料………………………………………………………………61 | |
| dc.language.iso | zh-TW | |
| dc.subject | 致癌基因 | zh_TW |
| dc.subject | 細胞凋亡 | zh_TW |
| dc.subject | 腺病毒 | zh_TW |
| dc.subject | 癌症 | zh_TW |
| dc.subject | 基因治療 | zh_TW |
| dc.subject | apoptosis | en |
| dc.subject | HER2 | en |
| dc.subject | siRNA | en |
| dc.subject | oncogene | en |
| dc.subject | cancer | en |
| dc.subject | CDDP | en |
| dc.subject | adenovirus | en |
| dc.title | 利用針對HER2/neu 原致癌基因的siRNA抑制HER2/neu大量表現癌細胞的致癌能力 | zh_TW |
| dc.title | Suppression of HER2/Neu-Overexpressing Cancers by siRNA against HER2/Neu Proto-Oncogene | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 94-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 黃麗華,陳小梨 | |
| dc.subject.keyword | 基因治療,癌症,致癌基因,細胞凋亡,腺病毒, | zh_TW |
| dc.subject.keyword | HER2,siRNA,oncogene,cancer,CDDP,apoptosis,adenovirus, | en |
| dc.relation.page | 67 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2006-07-23 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 微生物學研究所 | zh_TW |
| 顯示於系所單位： | 微生物學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-95-1.pdf 未授權公開取用 | 862.89 kB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。